Rosuvastatin Improves Endothelial Function in Ankylosing Spondylitis (CME/CE)
(MedPage Today) -- Reduced inflammation may reduce cardiovascular risks in AS patients. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - April 10, 2015 Category: Geriatrics Source Type: news
Rosuvastatin Cuts LDL and Carotid Stenosis in Inflamed Joints (CME/CE)
(MedPage Today) -- Study boosts link between RA patients and acute coronary syndromes. (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - March 27, 2015 Category: Rheumatology Source Type: news
Popular statin Rosuvastatin 'may raise the danger of diabetes'
There is growing evidence of weak benefits along with serious problems with rosuvastatin although it is the best statin for lowering cholesterol, says Dr Sidney Wolfe. (Source: the Mail online | Health)
Source: the Mail online | Health - March 18, 2015 Category: Consumer Health News Source Type: news
US doctor says FDA should have withdrawn rosuvastatin
Less beneficial and more risky than other statins and should not be prescribed, he claimsRelated items from OnMedicaNICE rejects arguments against wider statin useStatins associated with 46% increased diabetes riskOverview of risk assessment and statin therapyStatins and dietary changes have saved 20,000 livesDrugs regulators “put profits before patients” (Source: OnMedica Latest News)
Source: OnMedica Latest News - March 18, 2015 Category: UK Health Source Type: news
100 Most Prescribed, Best-Selling Branded Drugs Through September100 Most Prescribed, Best-Selling Branded Drugs Through September
The cholesterol-lowering drug rosuvastatin edged out the hypothyroid drug levothyroxine as the most prescribed drug in the United States, recent data show. Medscape Medical News (Source: Medscape Business of Medicine Headlines)
Source: Medscape Business of Medicine Headlines - November 3, 2014 Category: Pharmaceuticals Tags: Family Medicine/Primary Care News Source Type: news
100 Most Prescribed, Best-Selling Drugs Through September100 Most Prescribed, Best-Selling Drugs Through September
The cholesterol-lowering drug rosuvastatin edged out the hypothyroid drug levothyroxine as the most prescribed drug in the United States, recent data show. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 3, 2014 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news
Four ways to save on prescription drugs
Navigating the
annual health plan changes, figuring out insurance copays, and finding the
pharmacy with the best buys can be daunting. Dealing with Medicare's medication
coverage gap, the so-called donut hole, adds to the challenge. Four basic strategies can help save money on
medications, according to the November 2014 Harvard
Women's Health Watch.
Go for generics. "Generics are just as good as brand-name drugs," says Dr.
Jerry Avorn, professor of medicine at Harvard Medical School, and they are less
expensive than brand-name drugs. Can't find a generic version of a particular
drug? A prescription for a generic in t...
Source: New Harvard Health Information - October 30, 2014 Category: Consumer Health News Source Type: news
Potent Statin Offers No Help After Cardiac Surgery
BARCELONA (MedPage Today) -- Rosuvastatin (Crestor) -- a potent lipid-lowering agent thought to inhibit inflammation as well -- failed to prevent postoperative cardiac surgery complications such as atrial fibrillation. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 4, 2014 Category: Cardiology Source Type: news
Rosuvastatin Reduces Plaque Volume in STEMI PatientsRosuvastatin Reduces Plaque Volume in STEMI Patients
Rosuvastatin 40 mg reduced plaque burden in the non-infarct-related arteries of STEMI patients undergoing PCI. It did not, however, alter the phenotype of the lesion. Heartwire (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 2, 2014 Category: Consumer Health News Tags: Cardiology News Source Type: news
Rosuvastatin Slows Atherosclerosis in FH KidsRosuvastatin Slows Atherosclerosis in FH Kids
In the CHARON study, rosuvastatin was shown to be safe, effective, and capable of slowing the progression of atherosclerosis in young heterozygous FH patients. No risk for delayed physical or sexual maturation was reported. Heartwire (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 6, 2014 Category: Consumer Health News Tags: Cardiology News Source Type: news
Statins fail to reduce mortality rate in sepsis patients with ARDS
(Medical College of Wisconsin) Despite previously-reported observational and basic science evidence suggesting the use of statins may improve outcomes in patients with sepsis and acute respiratory distress syndrome, a double-blinded clinical trial of rosuvastatin in those patients was futile, and the study was halted. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 18, 2014 Category: Global & Universal Source Type: news
Statins aren't a wonder drug | Malcolm Kendrick
The claims made for statins are overblown. They are not a cure for most of the major diseases afflicting western civilisationStatins are the most widely prescribed drugs in medical history. They appear to have effortlessly conquered heart disease. If guidance proposed by Nice – the National Institute for Health and Care Excellence – is followed, 15 million people in the UK, most with no history of heart disease, could soon be taking them.A recent study by researchers at Imperial College London made the claim that "statins have virtually no side effects, with users experiencing fewer adverse symptoms than if they had ta...
Source: Guardian Unlimited Science - March 23, 2014 Category: Science Authors: Malcolm Kendrick Tags: Comment The Guardian World news Health Health policy Society Drugs UK news Statins Comment is free Source Type: news
Statins aren't a wonder drug | Malcolm Kendrick
This article was corrected on 24 March 2014. It originally said in the eighth paragraph: "Flecainide suppressed dangerous heart arrhythmias, but was pulled from the market for killing thousands of people." This has been amended, as the drug that was pulled from the market was encainide, not flecainide.StatinsDrugsHealthHealth policyMalcolm Kendricktheguardian.com © 2014 Guardian News and Media Limited or its affiliated companies. All rights reserved. | Use of this content is subject to our Terms & Conditions | More Feeds (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - March 23, 2014 Category: Science Authors: Malcolm Kendrick Tags: Statins Drugs Health Health policy Society UK news World news The Guardian Comment Comment is free Source Type: news
Study Examines the Effect of 24 Weeks of Statin Therapy on Systemic and Vascular Inflammation in HIV-Infected Participants on ART
“HIV-infected individuals are at increased cardiovascular disease (CVD) risk due in part to inflammation. Statins decrease inflammation in the general population, but their effect in HIV is largely unknown. … This is an on-going randomized, double-blinded, placebo-controlled trial to evaluate the effect of statins on inflammatory markers in HIV. Subjects received rosuvastatin 10 mg daily or placebo for 24 weeks. Subjects were receiving stable antiretroviral therapy with low-density lipoprotein (LDL)-cholesterol ≤130 mg/dL and evidence of heightened immune activation or inflammation. … 147 were enroll...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - January 17, 2014 Category: Infectious Diseases Source Type: news
McSweeney / Langevin Announces it is Providing Legal Advice to Woman...
The law firm McSweeney / Langevin is investigating legal claims on behalf of woman allegedly harmed by cholesterol lowering drugs Lipitor, Zocor and Crestor. The investigation follows the Food and...(PRWeb November 18, 2013)Read the full story at http://www.prweb.com/releases/2013/11/prweb11335102.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 19, 2013 Category: Pharmaceuticals Source Type: news
